LuciCapiva 200mg (Capivasertib)

Description

LuciCapiva 200mg (Capivasertib) is a targeted cancer medicine used to treat certain types of hormone receptor-positive (HR+), HER2-negative advanced or metastatic breast cancer, particularly when tumors have PIK3CA, AKT1, or PTEN gene alterations. It works by inhibiting the AKT signaling pathway, which helps slow the growth and spread of cancer cells.

Dosage:
The usual adult dose of LuciCapiva 200mg (Capivasertib) is 400 mg taken twice daily for 4 days followed by 3 days off, in combination with fulvestrant, or as directed by a healthcare professional.

Side Effects

Some patients using LuciCapiva 200mg (Capivasertib) may experience:

• Diarrhea
• Nausea
• Fatigue
• Skin rash
• Increased blood sugar levels

In rare cases, LuciCapiva 200mg may cause serious side effects such as severe skin reactions, dehydration from diarrhea, or high blood glucose levels. Patients should consult a doctor if symptoms become severe.

Prescribing Information

Before starting treatment, doctors may perform tests to confirm PIK3CA, AKT1, or PTEN gene alterations. LuciCapiva 200mg (Capivasertib) should only be used under the supervision of an experienced healthcare professional.

Patients should inform their doctor about all medications they are taking and avoid using LuciCapiva 200mg during pregnancy or breastfeeding.

Suggestion

For best results, take LuciCapiva 200mg (Capivasertib) exactly as prescribed. Do not change the dosage or stop treatment without consulting your doctor. Regular monitoring during treatment is recommended.

FAQ

What is LuciCapiva 200mg (Capivasertib) used for?
It is used to treat HR-positive, HER2-negative advanced breast cancer with specific genetic alterations.

How does LuciCapiva 200mg work?
LuciCapiva 200mg (Capivasertib) blocks the AKT pathway, which helps slow the growth of cancer cells.

How should LuciCapiva 200mg be taken?
It is usually taken twice daily for 4 days followed by 3 days off, as prescribed by a doctor.